Tokyo Tape
Sign in
← PHC Holdings

Half-year report · Q2

6523.TEDINET S100UR3H
Period2024-04-01 → 2024-09-30
Filed2024-11-13
StandardIFRS
ConsolidatedYes
Data checks12 of 12 passed
Key figures · 47
MetricValuePeriodScopeSource row
Revenue¥173.9bn2024-04-01 → 2024-09-30Cons.Revenue IFRS
Revenue¥353.9bn2023-04-01 → 2024-03-31Cons.Revenue IFRS (5-year summary)
Revenue¥166.8bn2023-04-01 → 2023-09-30Cons.Revenue IFRS
Operating income¥9.2bn2024-04-01 → 2024-09-30Cons.Operating profit loss IFRS
Operating income¥4.2bn2023-04-01 → 2023-09-30Cons.Operating profit loss IFRS
Profit before tax¥7.4bn2024-04-01 → 2024-09-30Cons.Profit loss before tax IFRS
Profit before tax−¥13.2bn2023-04-01 → 2024-03-31Cons.Profit loss before tax IFRS (5-year summary)
Profit before tax−¥3.0bn2023-04-01 → 2023-09-30Cons.Profit loss before tax IFRS
Net income (owners)¥4.1bn2024-04-01 → 2024-09-30Cons.Profit loss attributable to owners of parent IFRS
Net income (owners)−¥12.9bn2023-04-01 → 2024-03-31Cons.Profit loss attributable to owners of parent IFRS (5-year summary)
Net income (owners)−¥2.5bn2023-04-01 → 2023-09-30Cons.Profit loss attributable to owners of parent IFRS
Net income¥4.0bn2024-04-01 → 2024-09-30Cons.Profit loss IFRS
Net income−¥2.4bn2023-04-01 → 2023-09-30Cons.Profit loss IFRS
Total assets¥525.4bnat 2024-09-30Cons.Assets IFRS
Total assets¥564.3bnat 2024-03-31Cons.Assets IFRS
Total assets¥570.4bnat 2023-09-30Cons.Total assets IFRS (5-year summary)
Total liabilities¥398.0bnat 2024-09-30Cons.Liabilities IFRS
Total liabilities¥425.2bnat 2024-03-31Cons.Liabilities IFRS
Net assets / equity¥127.4bnat 2024-09-30Cons.Equity IFRS
Net assets / equity¥139.2bnat 2024-03-31Cons.Equity IFRS
Net assets / equity¥147.0bnat 2023-09-30Cons.Equity IFRS
Net assets / equity¥138.8bnat 2023-03-31dCons.Equity IFRS
Equity (owners)¥127.8bnat 2024-09-30Cons.Equity attributable to owners of parent IFRS
Equity (owners)¥139.5bnat 2024-03-31Cons.Equity attributable to owners of parent IFRS
Equity (owners)¥147.4bnat 2023-09-30Cons.Equity attributable to owners of parent IFRS (5-year summary)
Cash & equivalents¥33.0bnat 2024-09-30Cons.Cash and cash equivalents IFRS
Cash & equivalents¥47.0bnat 2024-03-31Cons.Cash and cash equivalents IFRS
Cash & equivalents¥61.4bnat 2023-09-30Cons.Cash and cash equivalents IFRS
Cash & equivalents¥60.9bnat 2023-03-31dCons.Cash and cash equivalents IFRS
Operating cash flow¥13.8bn2024-04-01 → 2024-09-30Cons.Net cash provided by used in operating activities IFRS
Operating cash flow¥41.3bn2023-04-01 → 2024-03-31Cons.Cash flows from used in operating activities IFRS (5-year summary)
Operating cash flow¥22.7bn2023-04-01 → 2023-09-30Cons.Net cash provided by used in operating activities IFRS
Investing cash flow−¥5.0bn2024-04-01 → 2024-09-30Cons.Net cash provided by used in investing activities IFRS
Investing cash flow−¥21.1bn2023-04-01 → 2024-03-31Cons.Cash flows from used in investing activities IFRS (5-year summary)
Investing cash flow−¥2.1bn2023-04-01 → 2023-09-30Cons.Net cash provided by used in investing activities IFRS
Financing cash flow−¥20.9bn2024-04-01 → 2024-09-30Cons.Net cash provided by used in financing activities IFRS
Financing cash flow−¥39.1bn2023-04-01 → 2024-03-31Cons.Cash flows from used in financing activities IFRS (5-year summary)
Financing cash flow−¥23.6bn2023-04-01 → 2023-09-30Cons.Net cash provided by used in financing activities IFRS
EPS (basic)¥32.522024-04-01 → 2024-09-30Cons.Basic earnings loss per share IFRS
EPS (basic)¥-102.482023-04-01 → 2024-03-31Cons.Basic earnings loss per share IFRS (5-year summary)
EPS (basic)¥-19.552023-04-01 → 2023-09-30Cons.Basic earnings loss per share IFRS
EPS (diluted)¥32.422024-04-01 → 2024-09-30Cons.Diluted earnings loss per share IFRS
EPS (diluted)¥-102.482023-04-01 → 2024-03-31Cons.Diluted earnings loss per share IFRS (5-year summary)
EPS (diluted)¥-19.552023-04-01 → 2023-09-30Cons.Diluted earnings loss per share IFRS
Equity ratio24.3%at 2024-09-30Cons.Ratio of owners equity to gross assets IFRS (5-year summary)
Equity ratio24.7%at 2024-03-31Cons.Ratio of owners equity to gross assets IFRS (5-year summary)
Equity ratio25.8%at 2023-09-30Cons.Ratio of owners equity to gross assets IFRS (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 30
SegmentItemPeriodValue
Reconciling Itemsreconcilingrevenue2024-04-01 → 2024-09-30¥1.6bn
Reconciling Itemsreconcilingrevenue external2024-04-01 → 2024-09-30¥1.6bn
Reconciling Itemsreconcilingsegment profit2024-04-01 → 2024-09-30−¥4.3bn
jpcrp040300-q2r_E36976-000Diabetes Managementreportable segmentrevenue2024-04-01 → 2024-09-30¥48.3bn
jpcrp040300-q2r_E36976-000Diabetes Managementreportable segmentrevenue external2024-04-01 → 2024-09-30¥48.3bn
jpcrp040300-q2r_E36976-000Diabetes Managementreportable segmentsegment profit2024-04-01 → 2024-09-30¥6.4bn
jpcrp040300-q2r_E36976-000Diagnostics And Life Sciencesreportable segmentrevenue2024-04-01 → 2024-09-30¥62.6bn
jpcrp040300-q2r_E36976-000Diagnostics And Life Sciencesreportable segmentrevenue external2024-04-01 → 2024-09-30¥62.6bn
jpcrp040300-q2r_E36976-000Diagnostics And Life Sciencesreportable segmentsegment profit2024-04-01 → 2024-09-30¥3.5bn
jpcrp040300-q2r_E36976-000Healthcare Solutionsreportable segmentrevenue2024-04-01 → 2024-09-30¥61.5bn
jpcrp040300-q2r_E36976-000Healthcare Solutionsreportable segmentrevenue external2024-04-01 → 2024-09-30¥61.5bn
jpcrp040300-q2r_E36976-000Healthcare Solutionsreportable segmentsegment profit2024-04-01 → 2024-09-30¥3.6bn
—segment totalrevenue2024-04-01 → 2024-09-30¥172.3bn
—segment totalrevenue external2024-04-01 → 2024-09-30¥172.3bn
—segment totalsegment profit2024-04-01 → 2024-09-30¥13.5bn
Reconciling Itemsreconcilingrevenue2023-04-01 → 2023-09-30¥1.1bn
Reconciling Itemsreconcilingrevenue external2023-04-01 → 2023-09-30¥1.1bn
Reconciling Itemsreconcilingsegment profit2023-04-01 → 2023-09-30−¥4.8bn
jpcrp040300-q2r_E36976-000Diabetes Managementreportable segmentrevenue2023-04-01 → 2023-09-30¥48.8bn
jpcrp040300-q2r_E36976-000Diabetes Managementreportable segmentrevenue external2023-04-01 → 2023-09-30¥48.8bn
jpcrp040300-q2r_E36976-000Diabetes Managementreportable segmentsegment profit2023-04-01 → 2023-09-30¥5.5bn
jpcrp040300-q2r_E36976-000Diagnostics And Life Sciencesreportable segmentrevenue2023-04-01 → 2023-09-30¥61.0bn
jpcrp040300-q2r_E36976-000Diagnostics And Life Sciencesreportable segmentrevenue external2023-04-01 → 2023-09-30¥61.0bn
jpcrp040300-q2r_E36976-000Diagnostics And Life Sciencesreportable segmentsegment profit2023-04-01 → 2023-09-30¥2.5bn
jpcrp040300-q2r_E36976-000Healthcare Solutionsreportable segmentrevenue2023-04-01 → 2023-09-30¥55.9bn
jpcrp040300-q2r_E36976-000Healthcare Solutionsreportable segmentrevenue external2023-04-01 → 2023-09-30¥55.9bn
jpcrp040300-q2r_E36976-000Healthcare Solutionsreportable segmentsegment profit2023-04-01 → 2023-09-30¥951m
—segment totalrevenue2023-04-01 → 2023-09-30¥165.7bn
—segment totalrevenue external2023-04-01 → 2023-09-30¥165.7bn
—segment totalsegment profit2023-04-01 → 2023-09-30¥8.9bn

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 812
ItemContextValueUnit
Total transactions with owners IFRSCurrentYTDDuration_ExchangeDifferencesOnTranslationOfForeignOperationsIFRSMember－JPY
Total transactions with owners IFRSCurrentYTDDuration_ShareOfOtherComprehensiveIncomeOfInvestmentsAccountedForUsingEquityMethodIFRSMember－JPY
Total transactions with owners IFRSCurrentYTDDuration_OtherComponentsOfEquityIFRSMember916000000JPY
Total transactions with owners IFRSCurrentYTDDuration_EquityAttributableToOwnersOfParentIFRSMember-2148000000JPY
Total transactions with owners IFRSCurrentYTDDuration_NonControllingInterestsIFRSMember－JPY
Total transactions with owners IFRSCurrentYTDDuration-2148000000JPY
Equity IFRSCurrentQuarterInstant_ExchangeDifferencesOnTranslationOfForeignOperationsIFRSMember42654000000JPY
Equity IFRSCurrentQuarterInstant_ShareOfOtherComprehensiveIncomeOfInvestmentsAccountedForUsingEquityMethodIFRSMember271000000JPY
Equity IFRSCurrentQuarterInstant_OtherComponentsOfEquityIFRSMember39887000000JPY
Equity IFRSCurrentQuarterInstant_EquityAttributableToOwnersOfParentIFRSMember127803000000JPY
Equity IFRSCurrentQuarterInstant_NonControllingInterestsIFRSMember-413000000JPY
Equity IFRSCurrentQuarterInstant127389000000JPY
Profit loss before tax IFRSPrior1YTDDuration-3030000000JPY
Profit loss before tax IFRSCurrentYTDDuration7411000000JPY
Depreciation and amortization ope cf IFRSPrior1YTDDuration13383000000JPY
Depreciation and amortization ope cf IFRSCurrentYTDDuration14310000000JPY
Impairment losses reversal of impairment losses ope cf IFRSPrior1YTDDuration2118000000JPY
Impairment losses reversal of impairment losses ope cf IFRSCurrentYTDDuration56000000JPY
Interest expenses ope cf IFRSPrior1YTDDuration3783000000JPY
Interest expenses ope cf IFRSCurrentYTDDuration3077000000JPY
Decrease increase in trade receivables ope cf IFRSPrior1YTDDuration8785000000JPY
Decrease increase in trade receivables ope cf IFRSCurrentYTDDuration8813000000JPY
Decrease increase in inventories ope cf IFRSPrior1YTDDuration-2959000000JPY
Decrease increase in inventories ope cf IFRSCurrentYTDDuration-4023000000JPY
Increase decrease in trade payables ope cf IFRSPrior1YTDDuration-2614000000JPY
Increase decrease in trade payables ope cf IFRSCurrentYTDDuration-4580000000JPY
Other changes in working capital ope cf IFRSPrior1YTDDuration2844000000JPY
Other changes in working capital ope cf IFRSCurrentYTDDuration-7761000000JPY
Subtotal ope cf IFRSPrior1YTDDuration22309000000JPY
Subtotal ope cf IFRSCurrentYTDDuration17303000000JPY
Interest and dividends received ope cf IFRSPrior1YTDDuration496000000JPY
Interest and dividends received ope cf IFRSCurrentYTDDuration205000000JPY
Interest paid ope cf IFRSPrior1YTDDuration-3290000000JPY
Interest paid ope cf IFRSCurrentYTDDuration-3381000000JPY
Income taxes paid ope cf IFRSPrior1YTDDuration-3267000000JPY
Income taxes paid ope cf IFRSCurrentYTDDuration-2454000000JPY
Income taxes refund ope cf IFRSPrior1YTDDuration6429000000JPY
Income taxes refund ope cf IFRSCurrentYTDDuration2093000000JPY
Net cash provided by used in operating activities IFRSPrior1YTDDuration22677000000JPY
Net cash provided by used in operating activities IFRSCurrentYTDDuration13767000000JPY
Purchase of property plant and equipment and intangible assets inv cf IFRSPrior1YTDDuration-6921000000JPY
Purchase of property plant and equipment and intangible assets inv cf IFRSCurrentYTDDuration-5897000000JPY
Proceeds from sale of property plant and equipment and intangible assets inv cf IFRSPrior1YTDDuration265000000JPY
Proceeds from sale of property plant and equipment and intangible assets inv cf IFRSCurrentYTDDuration206000000JPY
Proceeds from sale of investments accounted for using equity method inv cf IFRSPrior1YTDDuration3703000000JPY
Proceeds from sale of investments accounted for using equity method inv cf IFRSCurrentYTDDuration－JPY
Other inv cf IFRSPrior1YTDDuration828000000JPY
Other inv cf IFRSCurrentYTDDuration707000000JPY
Net cash provided by used in investing activities IFRSPrior1YTDDuration-2125000000JPY
Net cash provided by used in investing activities IFRSCurrentYTDDuration-4983000000JPY

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 12 of 12 passed
balance sheet identityconsolidated 2024-03-31pass rounding
balance sheet identityconsolidated 2024-09-30pass rounding
dei present pass
period resolution pass
statement vs summary · net income attributable to parentconsolidated 2023-04-01/2023-09-30pass
statement vs summary · net income attributable to parentconsolidated 2024-04-01/2024-09-30pass
statement vs summary · operating cash flowconsolidated 2023-04-01/2023-09-30pass
statement vs summary · operating cash flowconsolidated 2024-04-01/2024-09-30pass
statement vs summary · revenueconsolidated 2023-04-01/2023-09-30pass
statement vs summary · revenueconsolidated 2024-04-01/2024-09-30pass
statement vs summary · total assetsconsolidated 2024-03-31pass
statement vs summary · total assetsconsolidated 2024-09-30pass